Plasma Aβ42 as biomarker of prodromal AD progression in patients with amnestic mild cognitive impairment: evidence from the PharmaCog/E-ADNI study - Inria - Institut national de recherche en sciences et technologies du numérique Accéder directement au contenu
Article Dans Une Revue Journal of Alzheimer's Disease Année : 2019

Plasma Aβ42 as biomarker of prodromal AD progression in patients with amnestic mild cognitive impairment: evidence from the PharmaCog/E-ADNI study

1 IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri" [Milan, Italy]
2 IRCCS - Centro San Giovanni di Dio, Fatebenefratelli, Brescia
3 UNITN - Università degli Studi di Trento = University of Trento
4 UNIROMA - Università degli Studi di Roma "La Sapienza" = Sapienza University [Rome]
5 IRCCS-Hospital San Raffaele Pisana of Rome and Cassino
6 SDN - Istituto di Ricerca Diagnostica e Nucleare
7 INS - Institut de Neurosciences des Systèmes
8 TIMONE - Hôpital de la Timone [CHU - APHM]
9 Leipzig University / Universität Leipzig
10 Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
11 UniGe - Università degli studi di Genova = University of Genoa
12 UNIPG - Università degli Studi di Perugia = University of Perugia
13 ICHN - Imagerie cérébrale et handicaps neurologiques
14 Unicatt - Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart [Roma]
15 Fondazione Policlinico Universitario Agostino Gemelli IRCCS
16 Aristotle University of Thessaloniki
17 VUMC - Vrije Universiteit Medical Centre
18 GSK - GlaxoSmithKline [Stevenage, UK]
19 Universität Duisburg-Essen = University of Duisburg-Essen [Essen]
20 Georg-August-University = Georg-August-Universität Göttingen
21 CIDMA - University of Aveiro
22 TCDV - Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046
23 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
24 INT - Institut de Neurosciences de la Timone
25 IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri" [Milan, Italy]
26 UNIGE - Université de Genève = University of Geneva
Pieter Jelle Visser
Olivier Blin

Résumé

It is an open issue whether blood biomarkers serve to diagnose Alzheimer's disease (AD) or monitor its progression over time from prodromal stages. Here, we addressed this question starting from data of the European FP7 IMI-PharmaCog/E-ADNI longitudinal study in amnesic mild cognitive impairment (aMCI) patients including biological, clinical, neuropsychological (e.g., ADAS-Cog13), neuroimaging, and electroencephalographic measures. PharmaCog/E-ADNI patients were classified as "positive" (i.e., "prodromal AD" n = 76) or "negative" (n = 52) based on a diagnostic cut-off of Aβ42/P-tau in cerebrospinal fluid as well as APOE ε 4 genotype. Blood was sampled at baseline and at two follow-ups (12 and 18 months), when plasma amyloid peptide 42 and 40 (Aβ42, Aβ40) and apolipoprotein J (clusterin, CLU) were assessed. Linear Mixed Models found no significant differences in plasma molecules between the "positive" (i.e., prodromal AD) and "negative" groups at baseline. In contrast, plasma Aβ42 showed a greater reduction over time in the prodromal AD than the "negative" aMCI group (p = 0.048), while CLU and Aβ40 increased, but similarly in the two groups. Furthermore, plasma Aβ42 correlated with the ADAS-Cog13 score both in aMCI patients as a whole and the prodromal AD group alone. Finally, CLU correlated with the ADAS-Cog13 only in the whole aMCI group, and no association with ADAS-Cog13 was found for Aβ40. In conclusion, plasma Aβ42 showed disease progression-related features in aMCI patients with prodromal AD.
Fichier principal
Vignette du fichier
ALBANI ET AL_JAD BLOOD BIOMARKERS_2018 (1).pdf (1.4 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03575161 , version 1 (15-02-2022)

Identifiants

Citer

Diego Albani, Moira Marizzoni, Clarissa Ferrari, Federica Fusco, Lucia Boeri, et al.. Plasma Aβ42 as biomarker of prodromal AD progression in patients with amnestic mild cognitive impairment: evidence from the PharmaCog/E-ADNI study. Journal of Alzheimer's Disease, 2019, 69 (1), pp.37-48. ⟨10.3233/JAD-180321⟩. ⟨hal-03575161⟩
83 Consultations
50 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More